Respiratory syncytial virus (RSV) is a common, highly contagious illness that affects the nose, throat, and lungs. Although RSV usually causes mild illness with cold-like symptoms, the infection can ...

New real-world data suggests that seniors who get the RSV vaccine have an 80% lower odds for severe illness It's yet another reason to get immunized ahead of another RSV season Widespread immunization ...

Settlement will not change BD's cash flow goals or capital allocation strategy. FRANKLIN LAKES, N.J., Oct. 2, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global ...

RSV is a virus that can make people sick, especially older adults and babies. But even though RSV can be serious, people aren't as worried about it anymore. RSV is common but can be dangerous ...

AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections. The antibody ...

RSV is a highly contagious virus affecting the respiratory system, especially dangerous for infants, young children, and pregnant women. It leads to symptoms ranging from mild colds to severe ...

Today, we talk about some RSV competition that’s brewing, how Alnylam’s CEO spoke about its plans with ATTR-CM, and more. Alnylam Pharmaceuticals is expanding the footprint of its RNA-based ...

For some folks, the fall to-do list should now include an important third jab—a respiratory syncytial virus (RSV) vaccine. (The FDA approved the first one in 2023.) While flu and COVID cases ...

Rates of SUID per 100,000 live births rose by 10% from 2019 to 2021. A rise in rates of sudden unexpected infant deaths may have been linked to an off-season surge of respiratory syncytial virus ...

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization. With U.S ...